Saund Saran 4
4 · Oncotelic Therapeutics, Inc. · Filed Jul 16, 2021
Insider Transaction Report
Form 4
Saund Saran
CHIEF BUSINESS OFFICER
Transactions
- Conversion
Common Stock
2021-03-31+16,354,961→ 16,354,961 total - Award
Common Stock
2021-07-08+102,519→ 16,457,480 total - Award
Stock Options
2021-07-08+216,279→ 216,279 totalExercise: $0.16From: 2021-07-08Exp: 2031-07-08→ Common Stock (216,279 underlying) - Conversion
Series A Convertible Preferred Stock
2021-03-31−16,355→ 0 total→ Common Stock (16,354,961 underlying)
Footnotes (4)
- [F1]Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the "Merger"), shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.
- [F2]Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant.
- [F3]Shares of the Series A Convertible Preferred Stock does not expire.
- [F4]Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant.